O
Odd Terje Brustugun
Researcher at University of Oslo
Publications - 19
Citations - 2625
Odd Terje Brustugun is an academic researcher from University of Oslo. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 10, co-authored 19 publications receiving 2256 citations. Previous affiliations of Odd Terje Brustugun include Vestre Viken Hospital Trust & Oslo University Hospital.
Papers
More filters
Journal ArticleDOI
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
Martin Peifer,Lynnette Fernandez-Cuesta,Martin L. Sos,Julie George,Danila Seidel,Lawryn H. Kasper,Dennis Plenker,Frauke Leenders,Ruping Sun,Thomas Zander,Roopika Menon,Mirjam Koker,Ilona Dahmen,Christian Müller,Vincenzo Di Cerbo,Hans Ulrich Schildhaus,Janine Altmüller,Ingelore Baessmann,Christian Becker,Bram De Wilde,Jo Vandesompele,Diana Böhm,Sascha Ansén,Franziska Gabler,Ines Wilkening,Stefanie Heynck,Johannes M. Heuckmann,Xin Lu,Scott L. Carter,Kristian Cibulskis,Shantanu Banerji,Gad Getz,Kwon-Sik Park,Daniel Rauh,Christian Grütter,Matthias Fischer,Laura Pasqualucci,Gavin M. Wright,Zoe Wainer,Prudence A. Russell,Iver Petersen,Yuan Chen,Erich Stoelben,Corinna Ludwig,Philipp A. Schnabel,Hans Hoffmann,Thomas Muley,Michael Brockmann,Walburga Engel-Riedel,Lucia Anna Muscarella,Vito Michele Fazio,Harry J.M. Groen,Wim Timens,Hannie Sietsma,Erik Thunnissen,Egber Smit,Daniëlle A M Heideman,Peter J.F. Snijders,Federico Cappuzzo,C. Ligorio,Stefania Damiani,John K. Field,Steinar Solberg,Odd Terje Brustugun,Marius Lund-Iversen,Jörg Sänger,Joachim H. Clement,Alex Soltermann,Holger Moch,Walter Weder,Benjamin Solomon,Jean-Charles Soria,Pierre Validire,Benjamin Besse,Elisabeth Brambilla,Christian Brambilla,Sylvie Lantuejoul,Philippe Lorimier,Peter M. Schneider,Michael Hallek,William Pao,Matthew Meyerson,Matthew Meyerson,Julien Sage,Jay Shendure,Robert Schneider,Robert Schneider,Reinhard Büttner,Jürgen Wolf,Peter Nürnberg,Sven Perner,Lukas C. Heukamp,Paul K. Brindle,Stefan A. Haas,Roman K. Thomas +94 more
TL;DR: This study implicates histone modification as a major feature of SCLC, reveals potentially therapeutically tractable genomic alterations and provides a generalizable framework for the identification of biologically relevant genes in the context of high mutational background.
Journal ArticleDOI
Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
Peter S. Hammerman,Martin L. Sos,Alex H. Ramos,Chunxiao Xu,Amit Dutt,Wenjun Zhou,Lear E. Brace,Brittany Woods,Wenchu Lin,Jianming Zhang,Xianming Deng,Sang Min Lim,Stefanie Heynck,Martin Peifer,Jeffrey R. Simard,Michael S. Lawrence,Robert C. Onofrio,Helga B. Salvesen,Danila Seidel,Thomas Zander,Johannes M. Heuckmann,Alex Soltermann,Holger Moch,Mirjam Koker,Frauke Leenders,Frauke Leenders,Franziska Gabler,Silvia Querings,Sascha Ansén,Elisabeth Brambilla,Christian Brambilla,Philippe Lorimier,Odd Terje Brustugun,Åslaug Helland,Iver Petersen,Joachim H. Clement,Harry J.M. Groen,Wim Timens,Hannie Sietsma,Erich Stoelben,Juergen Wolf,David G. Beer,Ming-Sound Tsao,Megan Hanna,Megan Hanna,Charlie Hatton,Charlie Hatton,Michael J. Eck,Pasi A. Jänne,Bruce E. Johnson,Wendy Winckler,Heidi Greulich,Heidi Greulich,Adam J. Bass,Jeonghee Cho,Daniel Rauh,Nathanael S. Gray,Kwok-Kin Wong,Eric B. Haura,Roman K. Thomas,Matthew Meyerson,Matthew Meyerson +61 more
TL;DR: Findings suggest that gain-of-function mutations in DDR2 are important oncogenic events and are amenable to therapy with dasatinib, and provide a rationale for designing clinical trials with the FDA-approved drug d asatinib in patients with lung SCCs.
Journal ArticleDOI
A genomics-based classification of human lung tumors
Danila Seidel,Thomas Zander,Lukas C. Heukamp,Martin Peifer,Marc Bos,Lynnette Fernandez-Cuesta,Frauke Leenders,Xin Lu,Sascha Ansén,Masyar Gardizi,Chau Nguyen,Chau Nguyen,Johannes Berg,Prudence A. Russell,Zoe Wainer,Hans-Ulrich Schildhaus,Hans-Ulrich Schildhaus,Toni-Maree Rogers,Benjamin Solomon,William Pao,Scott L. Carter,Gad Getz,D. Neil Hayes,Matthew D. Wilkerson,Erik Thunnissen,William D. Travis,Sven Perner,Gavin M. Wright,Elisabeth Brambilla,Reinhard Buettner,Juergen Wolf,Roman K. Thomas,Franziska Gabler,Ines Wilkening,Christian Mueller,Ilona Dahmen,Roopika Menon,Katharina Koenig,Kerstin Albus,Sabine Merkelbach-Bruse,Jana Fassunke,Katja Schmitz,Helen Kuenstlinger,Michaela Angelika Kleine,Elke Binot,Silvia Querings,Janine Altmueller,Ingelore Boessmann,Peter Nuemberg,Peter M. Schneider,Magdalena Bogus,Alex Soltermann,Holger Moch,Odd Terje Brustugun,Steinar Solberg,Marius Lund-Iversen,Åslaug Helland,Thomas Muley,Hans Hoffmann,Philipp A. Schnabel,Yuan Chen,Harry J.M. Groen,Wim Timens,Hannie Sietsma,Joachim H. Clement,Walter Weder,Joerg Saenger,Erich Stoelben,Corinna Ludwig,Walburga Engel-Riedel,Egbert F. Smit,Danille A. M. Heideman,Peter J.F. Snijders,Lucia Nogova,Martin L. Sos,Christian Mattonet,Karin Toepelt,Matthias Scheffler,Eray Goekkurt,Eray Goekkurt,Rainer Kappes,Stefan Krueger,Kato Kambartel,Dirk Behringer,Wolfgang Schulte,Wolfgang Galetke,Winfried Randerath,Matthias Heldwein,Andreas Schlesinger,Monika Serke,Khosro Hekmat,Konrad Frank,Roland Schnell,Marcel Reiser,Ali-Nuri Huenerlituerkoglu,Stephan Schmitz,Lisa Meffert,Yon-Dschun Ko,Markus Litt-Lampe,Ulrich Gerigk,Rainer Fricke,Benjamin Besse,Christian Brambilla,Sylvie Lantuejoul,Philippe Lorimier,Denis Moro-Sibilot,Federico Cappuzzo,C. Ligorio,Stefania Damiani,John K. Field,Russell Hyde,Pierre Validire,Philippe Girard,Lucia Anna Muscarella,Vito Michele Fazio,Michael Hallek,Jean-Charles Soria,Viktor Achter,Ulrich Lang +118 more
TL;DR: Support is provided for broad implementation of genome-based diagnosis of lung cancer by demonstrating the correlation between lung tumor subtype and its predominant mutations, and the benefit of genetic testing and targeted therapy in these patients.
Journal ArticleDOI
Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors
Julie George,Vonn Walter,Vonn Walter,Martin Peifer,Ludmil B. Alexandrov,Danila Seidel,Frauke Leenders,Lukas Maas,Christian Müller,Ilona Dahmen,Tiffany M. Delhomme,Maude Ardin,Noémie Leblay,Graham Byrnes,Ruping Sun,Aurélien de Reyniès,Anne McLeer-Florin,Graziella Bosco,Florian Malchers,Roopika Menon,Janine Altmüller,Christian Becker,Peter Nürnberg,Viktor Achter,Ulrich Lang,Peter M. Schneider,Magdalena Bogus,Matthew G. Soloway,Matthew D. Wilkerson,Yupeng Cun,James McKay,Denis Moro-Sibilot,Christian Brambilla,Sylvie Lantuejoul,Nicolas Lemaitre,Alex Soltermann,Walter Weder,Verena Tischler,Odd Terje Brustugun,Odd Terje Brustugun,Marius Lund-Iversen,Åslaug Helland,Åslaug Helland,Steinar Solberg,Sascha Ansén,Gavin M. Wright,Benjamin Solomon,Luca Roz,Ugo Pastorino,Iver Petersen,Joachim H. Clement,Jörg Sänger,Jürgen Wolf,Martin Vingron,Thomas Zander,Sven Perner,William D. Travis,Stefan A. Haas,Magali Olivier,Matthieu Foll,Reinhard Büttner,David N. Hayes,Elisabeth Brambilla,Lynnette Fernandez-Cuesta,Lynnette Fernandez-Cuesta,Roman K. Thomas,Roman K. Thomas +66 more
TL;DR: It is shown LCNECs represent a distinct transcriptional subgroup among lung cancers and comprise two molecular subgroups, type I (TP53 and STK11/KEAP1 alterations) and type II ( TP53 and RB1 inactivation).
Journal ArticleDOI
BRAF-mutations in non-small cell lung cancer
Odd Terje Brustugun,Odd Terje Brustugun,Asma Malik Khattak,Anette Kjoshagen Trømborg,Marzieh Beigi,Klaus Beiske,Marius Lund-Iversen,Åslaug Helland,Åslaug Helland +8 more
TL;DR: Clinopathological characteristics of nearly one thousand unselected NSCLC patients tested for the targetable V600E/K BRAF-mutation should be part of the subtyping of non-squamous NSCLc.